| Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China (NCT05199571) | Novartis Pharmaceuticals | 2022-07-22 |
| A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis (NCT05344469) | Novartis Pharmaceuticals | 2022-05-10 |
| A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (NCT05232825) | Hoffmann-La Roche | 2022-05-03 |
| A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) (NCT05119569) | Hoffmann-La Roche | 2022-03-01 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) (NCT05147220) | Novartis Pharmaceuticals | 2021-12-16 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) (NCT05156281) | Novartis Pharmaceuticals | 2021-12-13 |
| Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis (NCT05077956) | Providence Health & Services | 2021-10-19 |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (NCT04079088) | Biogen | 2021-06-30 |
| Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab (NCT04869358) | Novartis Pharmaceuticals | 2021-05-27 |
| A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab (NCT04847596) | Novartis Pharmaceuticals | 2021-05-21 |
| Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (NCT04586023) | Hoffmann-La Roche | 2021-03-24 |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (NCT04586010) | Hoffmann-La Roche | 2021-03-17 |
| Effects of Ocrevus in Relapsing Multiple Sclerosis (NCT04387734) | Georgia State University | 2021-02-05 |
| A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab (NCT04667117) | Novartis Pharmaceuticals | 2021-01-14 |
| A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis (NCT04626921) | Clene Nanomedicine | 2020-10-22 |
| A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis (NCT04486716) | Novartis Pharmaceuticals | 2020-10-19 |
| 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis (NCT04510220) | Brigham and Women's Hospital | 2020-09-21 |
| Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) (NCT04121065) | Neuromed IRCCS | 2020-09-07 |
| Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset (NCT04466150) | University of California, San Francisco | 2020-08-30 |
| An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (NCT04353492) | Novartis Pharmaceuticals | 2020-07-14 |
| Study of Evobrutinib in Participants With RMS (evolutionRMS 2) (NCT04338061) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-07-02 |
| Study of Evobrutinib in Participants With RMS (evolutionRMS 1) (NCT04338022) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-06-12 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (NCT04410991) | Sanofi | 2020-06-11 |
| Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) (NCT04121403) | Oslo University Hospital | 2019-10-16 |
| Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis (NCT03996291) | Sanofi | 2019-09-23 |
| Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis (NCT03889639) | Sanofi | 2019-03-29 |
| To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (NCT03856619) | Sanofi | 2019-03-27 |
| Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (NCT03623243) | Novartis Pharmaceuticals | 2019-02-14 |
| Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (NCT03650114) | Novartis Pharmaceuticals | 2018-12-28 |
| Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab (NCT03249714) | Novartis Pharmaceuticals | 2018-03-15 |
| A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod (NCT03257358) | Novartis Pharmaceuticals | 2017-09-19 |
| Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients (NCT03183869) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2017-08-24 |
| Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (NCT02792218) | Novartis Pharmaceuticals | 2016-09-20 |
| Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran (NCT04928313) | Cinnagen | 2015-04-12 |
| Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (NCT02254304) | Merck KGaA, Darmstadt, Germany | 2014-12-31 |
| Natalizumab Subcutaneous Immunogenicity and Safety Study (NCT02142192) | Biogen | 2014-12-01 |
| Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (NCT02234869) | Biogen | 2014-10-01 |
| Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies (NCT02241785) | Biogen | 2014-09-30 |
| Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (NCT02047734) | Celgene | 2013-12-03 |
| Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (NCT01939002) | Biogen | 2013-11-01 |
| Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (NCT01628393) | Celgene | 2012-09-18 |
| An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device (NCT01601080) | Merck KGaA, Darmstadt, Germany | 2012-04-01 |
| A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability (NCT01404117) | Teva Branded Pharmaceutical Products R&D, Inc. | 2012-03-01 |
| Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients (NCT01601119) | Merck KGaA, Darmstadt, Germany | 2012-01-01 |
| A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (NCT01412333) | Hoffmann-La Roche | 2011-09-20 |
| A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (NCT01247324) | Hoffmann-La Roche | 2011-08-31 |
| Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (NCT01332019) | Biogen | 2011-04-01 |
| Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) (NCT01199861) | Novartis | 2010-08-01 |
| A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis (NCT01047319) | Teva Branded Pharmaceutical Products R&D, Inc. | 2010-05-27 |
| Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study (NCT01006941) | Rigshospitalet, Denmark | 2010-05-01 |
| Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients (NCT01127750) | Novartis | 2010-05-01 |
| JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab (NCT01070836) | Biogen | 2010-03-01 |
| The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial (NCT01034579) | EMD Serono | 2010-02-01 |
| Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (NCT00906399) | Biogen | 2009-06-01 |
| Atacicept in Multiple Sclerosis Extension Study, Phase II (NCT00853762) | EMD Serono | 2009-03-01 |
| A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) (NCT00642902) | EMD Serono | 2008-04-01 |
| Transition to Rebif New Formulation (NCT00619307) | Merck KGaA, Darmstadt, Germany | 2007-07-01 |
| Rebif New Formulation (RNF) Quality of Life (QOL) Study (NCT00472797) | EMD Serono | 2007-04-01 |